Trial Profile
A Phase I, Open Label, Dual Cohort, Single Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Autologous CD4 T Cells Modified With a Retroviral Vector Expressing the MazF Endoribonuclease Gene in Patients With HIV
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs HIV-1 gene therapy (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 29 Aug 2019 Status changed from active, no longer recruiting to completed.
- 14 Jun 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.
- 11 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.